Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

 
• By Reed Miller

The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.

Respicardia Inc.'s remedē neurostimulation system significantly reduced the severity of central sleep apnea and improved sleep apnea patients' arousal, self-reported sleepiness, REM sleep, and quality-of-life scores in the pivotal trial of the transvenous implantable device.

Six-month follow-up data from the 151-patient randomized trial, led by Maria Rosa Costanzo of the Advocate Heart Institute in Naperville, Ill., were published online by The Lancet on Sept. 1 and were also reported in May at the European Society of Cardiology – Heart Failure meeting. "Transvenous neurostimulation might offer a new therapeutic approach to the treatment of central sleep apnea," Costanzo and colleagues explain

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Business